Kiadis Raises €28m As Cell Therapy Nears Commercialization
Executive Summary
The funding comes as the Dutch biotech closes in on a potential conditional approval and closure of its acquisition of CytoSen.
You may also be interested in...
Kiadis Crushed By EMA Rejection Of T-Cell Therapy
The Dutch company's dataset on its stem cell transplant adjunct ATIR101 is not enough to satisfy European regulators as the standard of care in post-transplant patients has changed since the original filing.
Kiadis Still Betting On Blood Cancer Immunotherapy Launch This Year
Kiadis has conducted further analyses of data on its investigational blood cancer therapy ATIR101 and is now hoping to secure EU approval in time for the therapy to be used in the first patients by the end of 2019.
Executives On The Move: Changes At The Top At Viatris And Clinuvel Among This Week's Announcements
Recent moves in the industry include C-suite shuffle at Brainstorm Cell Therapeutics and new CFOs at Faron Pharmaceuticals and Foghorn Therapeutics, among others.